Multimodal Clinical Study of Electroconvulsive Therapy and Magnetic Seizure Therapy
Status: Recruiting
Location: See location...
Intervention Type: Other, Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
To compare the efficacy and tolerability of Electroconvulsive Therapy (ECT) and Magnetic Seizure Therapy (MST) in patients with major depressive disorder (MDD).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Maximum Age: 80
Healthy Volunteers: t
View:
• Aged 12-80 years; Diagnosis confirmed by two psychiatrists per DSM-5; Stable medication regimen pre-enrollment; Indicated for neuromodulation OR with visual field defects.
• Aged 12-80 years; No history of neuropsychiatric disorders; No significant systemic diseases; Normal or corrected vision.
Locations
Other Locations
China
Anhui Medical University
RECRUITING
Hefei
Contact Information
Primary
Yanghua Tian PhD
zylykd@163.com
0551 6599 7278
Time Frame
Start Date: 2025-09-01
Estimated Completion Date: 2028-01
Participants
Target number of participants: 200
Treatments
Experimental: Electroconvulsive Therapy (ECT) Group
Participants with Major Depressive Disorder(MDD) receive active Electroconvulsive Therapy (ECT) according to the study protocol, in addition to their ongoing standardized pharmacotherapy. This group assesses the efficacy and cognitive effects of ECT.
Experimental: Magnetic Seizure Therapy (MST) Group
Participants with Major Depressive Disorder (MDD) receive active Magnetic Seizure Therapy (MST) according to the study protocol, in addition to their ongoing standardized pharmacotherapy. This group assesses the efficacy and cognitive effects of MST, allowing for comparison with ECT.
Other: Healthy Control Group
Healthy volunteers with no history of major neuropsychiatric disorders. They do not receive any neuromodulation intervention (ECT or MST) or study-related pharmacotherapy. They undergo the same cognitive and behavioral assessments at matched time points to provide normative baseline data for comparison.
Related Therapeutic Areas
Sponsors
Leads: The Second Hospital of Anhui Medical University